NASDAQ:ARQL

Delisted

Arqule Stock News

Buy ARQL

*Your capital is at risk

$20.00

+0 (+0%)

At Close: Apr 15, 2020

ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting

07:00am, Monday, 25'th Nov 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that final clinical data from the company-sponsored phase 1 study of ARQ 531 will be presented on December 9, 2019 at th

ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019

07:00am, Wednesday, 16'th Oct 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2019 before the market opens on Wednesday, October 30, 2019. T

ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019

07:00am, Wednesday, 24'th Jul 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019. Th

ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA)

07:00am, Friday, 07'th Jun 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL), today announced that it will present clinical data from the company-sponsored phase 1 dose escalation study on its BTK inhibitor, ARQ 5

ArQule to Report First Quarter 2019 Financial Results on May 1, 2019

04:01pm, Wednesday, 17'th Apr 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2019 before the market opens on Wednesday, May 1, 2019. The Co

ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

07:00am, Thursday, 21'st Feb 2019

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March

ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting

07:00am, Monday, 03'rd Dec 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent a

ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018

07:00am, Wednesday, 17'th Oct 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter of 2018 before the market opens on Wednesday, October 31, 2018. T

ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018

06:18pm, Wednesday, 18'th Jul 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2018 before the market opens on Wednesday, August 1, 2018. Th

ArQule to Report First Quarter 2018 Financial Results on May 7, 2018

04:35pm, Monday, 23'rd Apr 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2018 before the market opens on Monday, May 7, 2018. The Compa

ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China

07:00am, Tuesday, 17'th Apr 2018

BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ:ARQL) today announced that it has entered into an exclusive license agreement with Basilea Pharmaceutica International Limited (Basilea, SIX: B

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by